Skye Bioscience Inc.

SKYE | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.73

-$0.05 (-2.81%)

Sep 22, 2026, 2:03 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.81%

(1D)

Rating

Updated: Aug 17, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $7.6M

1D Range

1.73 1.82

52W Range

1.50 39.92

Valuation (TTM)

PE -0.18

PB -15.72

EV/EBITDA 0.04

Valuation (NTM)

Forward PE N/A

Forward PEG -0.01

Price Target $12

Cash Flow

FCF Yield -496.3%

SBC Adj. FCF Yield 27554.2%

SBC Impact -5651.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 63.5% | 45.1%

FCF 3Y | 5Y -0.3% | -49.8%

Returns

ROA -457.6%

ROE -329.1%

ROIC 11242.3%

Financial Health

Net Cash

$10.06M

Current Ratio 0.95

Interest Coverage -9,439.02

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. I...

Sector Healthcare

Industry Biotechnology

Employees 2

IPO Date Jan 5, 2015

Website skyebioscience.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.